News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,028 Results
Type
Article (42437)
Company Profile (436)
Press Release (673155)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (208820)
Career Advice (2049)
Deals (36023)
Drug Delivery (104)
Drug Development (83635)
Employer Resources (173)
FDA (16452)
Job Trends (15115)
News (353000)
Policy (33115)
Tag
Academia (2646)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (50999)
ALS (100)
Alzheimer's disease (1436)
Antibody-drug conjugate (ADC) (147)
Approvals (16433)
Artificial intelligence (279)
Autoimmune disease (26)
Automation (16)
Bankruptcy (372)
Best Places to Work (11848)
BIOSECURE Act (19)
Biosimilars (108)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (28)
Breast cancer (300)
Cancer (2379)
Cardiovascular disease (191)
Career advice (1710)
Career pathing (30)
CAR-T (161)
Cell therapy (456)
Cervical cancer (20)
Clinical research (67903)
Collaboration (900)
Company closure (2)
Compensation (566)
Complete response letters (24)
COVID-19 (2654)
CRISPR (47)
C-suite (262)
Cystic fibrosis (106)
Data (2335)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6440)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (111)
Drug shortages (26)
Duchenne muscular dystrophy (103)
Earnings (88236)
Editorial (43)
Employer branding (21)
Employer resources (147)
Events (116242)
Executive appointments (758)
FDA (17837)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (802)
Gene editing (119)
Generative AI (20)
Gene therapy (338)
GLP-1 (757)
Government (4521)
Grass and pollen (4)
Guidances (150)
Healthcare (19161)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (137)
Indications (30)
Infectious disease (2801)
Inflammatory bowel disease (150)
Inflation Reduction Act (11)
Influenza (53)
Intellectual property (99)
Interviews (321)
IPO (16808)
IRA (43)
Job creations (3706)
Job search strategy (1449)
Kidney cancer (10)
Labor market (43)
Layoffs (506)
Leadership (20)
Legal (7992)
Liver cancer (77)
Lung cancer (333)
Lymphoma (158)
Machine learning (9)
Management (58)
Manufacturing (332)
MASH (76)
Medical device (13539)
Medtech (13544)
Mergers & acquisitions (19778)
Metabolic disorders (738)
Multiple sclerosis (85)
NASH (19)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2024)
NextGen: Class of 2025 (6758)
Non-profit (4551)
Now hiring (40)
Obesity (394)
Opinion (225)
Ovarian cancer (82)
Pain (96)
Pancreatic cancer (89)
Parkinson's disease (157)
Partnered (21)
Patents (245)
Patient recruitment (117)
Peanut (47)
People (58740)
Pharmaceutical (86)
Pharmacy benefit managers (20)
Phase I (21336)
Phase II (29973)
Phase III (22145)
Pipeline (1369)
Policy (155)
Postmarket research (2601)
Preclinical (9161)
Press Release (67)
Prostate cancer (111)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (409)
Real estate (6017)
Recruiting (66)
Regulatory (22808)
Reports (47)
Research institute (2419)
Resumes & cover letters (353)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (141)
Series B (93)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3768)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (48)
The Weekly (49)
Vaccines (717)
Venture capitalists (44)
Weight loss (257)
Women's health (38)
Worklife (17)
Date
Today (185)
Last 7 days (954)
Last 30 days (3159)
Last 365 days (33469)
2025 (11998)
2024 (36317)
2023 (41025)
2022 (52288)
2021 (56776)
2020 (54944)
2019 (47438)
2018 (35720)
2017 (33042)
2016 (32369)
2015 (38413)
2014 (32206)
2013 (27123)
2012 (29238)
2011 (29877)
2010 (28003)
Location
Africa (738)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39332)
Australia (6540)
California (6512)
Canada (2074)
China (547)
Colorado (278)
Connecticut (293)
Delaware (159)
Europe (86050)
Florida (950)
Georgia (213)
Idaho (57)
Illinois (566)
India (25)
Indiana (322)
Iowa (12)
Japan (173)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (939)
Massachusetts (4925)
Michigan (225)
Minnesota (408)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (67)
New Hampshire (67)
New Jersey (1821)
New Mexico (30)
New York (1821)
North Carolina (1055)
North Dakota (8)
Northern California (2838)
Ohio (211)
Oklahoma (14)
Oregon (38)
Pennsylvania (1435)
Puerto Rico (13)
Rhode Island (34)
South America (1114)
South Carolina (25)
South Dakota (1)
Southern California (2440)
Tennessee (105)
Texas (964)
United States (24493)
Utah (191)
Virginia (156)
Washington D.C. (66)
Washington State (585)
West Virginia (3)
Wisconsin (57)
716,028 Results for "an2 therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
April 30, 2025
·
1 min read
Press Releases
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
March 3, 2025
·
1 min read
Press Releases
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
March 25, 2025
·
10 min read
Layoffs
AN2 Therapeutics Laying Off Half Its Workforce
AN2 is discontinuing a study that evaluated epetraborole for treatment-refractory MAC lung disease and plans to shift focus to its boron chemistry platform.
August 9, 2024
·
1 min read
·
Angela Gabriel
Press Releases
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
May 1, 2025
·
9 min read
Press Releases
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 30, 2025
·
1 min read
Press Releases
AN2 Therapeutics to Participate at Upcoming Investor Conferences
November 14, 2024
·
1 min read
Business
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.
May 14, 2024
·
8 min read
Biotech Bay
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
January 30, 2024
·
1 min read
Press Releases
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
February 24, 2025
·
7 min read
1 of 71,603
Next
